H.C. Wainwright assumes coverage on Can-Fite BioPharma stock with Buy rating
PositiveFinancial Markets

H.C. Wainwright has initiated coverage on Can-Fite BioPharma with a Buy rating, signaling strong confidence in the company's potential for growth. This move is significant as it highlights the increasing interest in Can-Fite's innovative therapies, which could lead to greater investment and support for their ongoing projects. Investors should pay attention to this development as it may influence market perceptions and stock performance.
— Curated by the World Pulse Now AI Editorial System









